<a href="https://laohu8.com/S/IMAB">I-Mab</a> Announces Global Phase 2 Trial Initiation for Givastomig in Metastatic Gastric Cancers, Set for Q1 2026
I-Mab, a global biotech company, has announced an acceleration in the investment for its lead program, givastomig, an investigational bispecific antibody targeting Claudin 18.2 (CLDN18.2) for the treatment of metastatic gastric cancers. The company plans to initiate a global randomized Phase 2 study of givastomig in combination with immunochemotherapy in the first quarter of 2026. Additionally, I-Mab aims to report topline data from its Phase 1b dose expansion study, which is evaluating givastomig at two dose levels in combination with nivolumab and chemotherapy, in the first quarter of 2026. The development strategy will also be broadened to include locally advanced gastric cancer and other Claudin 18.2-positive tumor types, such as biliary tract cancer and pancreatic ductal adenocarcinoma.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. I-Mab published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-113369), on September 08, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。